The 28 references in paper S. Avdeev N., Z. Aisanov R., A. Belevskiy S., A. Vizel' A., S. Zyryanov K., G. Ignatova L., N. Knyazheskaya P., I. Leshchenko V., S. Ovcharenko I., A. Sinopal'nikov I., I. Stepanyan E., V. Trofimov I., С. Авдеев Н., З. Айсанов Р., А. Белевский С., А. Визель А., С. Зырянов К., Г. Игнатова Л., Н. Княжеская П., И. Лещенко В., С. Овчаренко И., А. Синопальников И., И. Степанян Э., В. Трофимов И. (2017) “Новые возможности в профилактике обострений хронической обструктивной болезни легких. Заключение группы специалистов Российского респираторного общества // New opportunities for prevention of exacerbations of chronic obstructive pulmonary disease. Russian Respiratory Society Expert Opinion” / spz:neicon:pulmonology:y:2017:i:1:p:108-113

1
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Revised
(check this in PDF content)
2
17.www.goldcopd.org.Accessed February 26, 2017. 2. Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study.Eur. Respir. J.2013; 42 (6): 1484–1494. DOI: 10.1183/09031936.00200212.
(check this in PDF content)
3
Singh D., Jones P.W., Bateman E.D. et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixeddose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm. Med.2014; 14: 178. DOI: 10.1186/1471-2466-14-178.
(check this in PDF content)
4
Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur. Respir. J.2015; 45 (4): 969–979. DOI: 10.1183/09031936.00136014.
(check this in PDF content)
5
Decramer M., Anzueto A., Kerwin E. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir. Med.2014; 2 (6): 472–486. DOI: 10.1016/ S2213-2600(14)70065-7.
(check this in PDF content)
6
Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir. Med.2013; 1 (1): 51–60. DOI: 10.1016/S2213-2600(12)70052-8.
(check this in PDF content)
7
Beeh K.M., Derom E., Echave-Sustaeta J. et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat®is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler®(ENERGITO® study).Int. J. Chron. Obstruct. Pulmon. Dis.2016; 11: 193–205. DOI: 10.2147/COPD.S95055.
(check this in PDF content)
8
Singh D., Worsley S., Zhu C.Q. et al. Umeclidinium/ vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm. Med.2015; 15: 91. DOI: 10.1186/s12890-015-0092-1.
(check this in PDF content)
9
Vogelmeier С.F., Paggiaro P.L., Dorca J. et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.Eur. Respir. J. 2016; 48 (4):
(check this in PDF content)
10
0–1039. DOI: 10.1183/13993003.00216-2016. 10. Mahler D.A., Decramer M., D'Urzo A. et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study.Eur. Respir. J. 2014; 43 (6): 1599–1609. DOI: 10.1183/09031936.00124013.
(check this in PDF content)
11
Chapman K.R., Bateman E.D., Chen H. et al. QVA149 improves lung function, dyspnea, and health status independent of previously prescribed medications and COPD severity: A subgroup analysis from the SHINE and ILLUMINATE studies. J. COPD F.2015; 2 (1): 48–60. DOI: 10.15326.
(check this in PDF content)
12
Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, doubleblind, parallel-group study.Lancet Respir. Med.2013; 1 (3): 199–209.
(check this in PDF content)
13
Wedzicha J.A. et al. Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD. N. Eng. J. Med.2016; 374 (23): 2222–2234. DOI: 10.1016/S2213-2600(13)70052-3.
(check this in PDF content)
14
Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomised trial. Ann. Intern. Med. 2007; 146 (8): 545–555. DOI: 10.7326/0003-4819-146-8200704170-00152.
(check this in PDF content)
15
Welte T., Miravitlles M., Hernandez P. et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180 (8): 741–750. DOI: 10.1164/rccm.200904-0492OC.
(check this in PDF content)
16
Karner C., Cates C.J. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (3): CD008532. DOI: 10.1002/14651858.CD008532.pub2.
(check this in PDF content)
17
Singh D., Papi А., Corradi M. et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomized controlled trial. Lancet. 2016; 388: 963–973. DOI: 10.1016/S0140-6736(16)31354-X.
(check this in PDF content)
18
Singh D., Schröder-Babo W., Cohuet G. et al. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study). Respir. Med.2016; 114: 84–90. DOI: 10.1016/j.rmed.2016.03.018.
(check this in PDF content)
19
Loke Y.K., Cavallazzi R., Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011; 66 (8): 699–708. DOI: 10.1136/thx.2011.160028.
(check this in PDF content)
20
Nannini L.J., Cates C.J., Lasserson T.J., Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2007; (4): CD003794. DOI: 10.1002/14651858.CD003794.pub3.
(check this in PDF content)
21
Suissa S., Patenaude V., Lapi F., Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013; 68 (11): 1029–1036. DOI: 10.1136/thoraxjnl-2012202872.
(check this in PDF content)
22
Janson C., Larsson K., Lisspers K.H. et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroids and long acting β2-agonist: observational matched cohort study (PATHOS). Br. Med. J.2013; 346: f3306. DOI: 10.1136/ bmj.f3306.
(check this in PDF content)
23
Kew K.M., Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.2014; (3): CD010115. DOI: 10.1002/14651858.CD010115.pub2.
(check this in PDF content)
24
Yang I.A., Clarke M.S., Sim E.H.A., Fong K.M. Inhaled corticosteroids for stable chronic obstructive pulmonary disease.Cochrane Database Syst. Rev.2012; (7): CD002991. DOI: 10.1002/14651858.CD002991.pub3.
(check this in PDF content)
25
Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am. J. Med. 2010; 123 (11): 1001–1006. DOI: 10.1016/j.amjmed.2010. 06.019.
(check this in PDF content)
26
Ferreira A.J. et al. COPD: A stepwise or a hit hard approach?Rev. Port. Pneumol. 2016; 22 (4): 214–221. DOI: 10.1016/j.rppnen.2015.12.012.
(check this in PDF content)
27
Magnussen H., Watz H., Kirsten A. et al. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale. Respir. Med. 2014; 108 (4): 593–599. DOI: http: 10.1016/j.rmed.2014.01.002.
(check this in PDF content)
28
Kaplan A.G. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice.Int. J. COPD.2015; 10 (1): 2535–2548. DOI: 10.2147/COPD.S93321. Поступила 28.02.17
(check this in PDF content)